Which Pharma and Healthcare Stocks Are Emerging Stronger in Q2 FY26?
About the Pharma and Healthcare Landscape
The Indian pharmaceutical and healthcare industry continues to evolve post-pandemic, with companies focusing on cost control, product diversification, and global regulatory clearances. Domestic demand is steady, while export momentum in generics, injectables, and contract manufacturing supports revenue visibility.
Unichem Laboratories Q2 Results
| Metric | Q2 FY26 | YoY |
|---|---|---|
| Revenue | ₹578 Cr | ₹507 Cr |
| EBITDA | ₹66.1 Cr | ₹55.49 Cr |
| Margins | 11.43% | 10.93% |
| Net Result | Loss ₹11.8 Cr | Profit ₹24.6 Cr |
Unichem Laboratories recorded a loss due to an exceptional item of ₹58 Cr. Excluding this, profit before exceptional items stood at ₹47.4 Cr vs ₹27.12 Cr YoY. The management continues to focus on regulated market approvals and API exports.
Investors tracking pharma counters for value re-rating may follow sectoral setups using Nifty Derivative Tip | BankNifty Derivative Tip.
Emcure Pharmaceuticals Q2 Highlights
Emcure Pharmaceuticals reported strong operational growth with revenue at ₹2,269 Cr vs ₹2,001 Cr YoY and EBITDA at ₹474 Cr vs ₹380 Cr. Margins improved to 20.94%, reflecting scale benefits and disciplined cost control. Net profit rose to ₹251 Cr vs ₹201 Cr YoY, underlining resilience in chronic therapy and international business segments.
Orchid Pharma: Challenging Quarter
Orchid Pharma reported an EBITDA loss of ₹1.48 Cr vs ₹30.33 Cr profit YoY, with revenue declining to ₹195 Cr from ₹229 Cr. The company continues restructuring efforts to stabilize operations and control fixed costs while exploring partnerships in active pharmaceutical ingredients (APIs).
Anlon Healthcare: Robust Margin Expansion
| Metric | Q2 FY26 | YoY |
|---|---|---|
| Revenue | ₹52.2 Cr | ₹24.16 Cr |
| EBITDA | ₹13.73 Cr | ₹7.52 Cr |
| Margins | 26.3% | 31.1% |
| Net Profit | ₹9.31 Cr | ₹2.59 Cr |
Anlon Healthcare continues to outperform peers with margin leadership and a diversified product mix across diagnostics and pharmaceuticals.
Jeena Sikho Lifecare: Corporate Tie-Up with Maruti Suzuki
Jeena Sikho Lifecare was empanelled with Maruti Suzuki for cashless Ayurveda Panchkarma treatments at its Murad Nagar, Gurugram, and Manesar hospitals. This tie-up strengthens its institutional presence and corporate healthcare offerings, enhancing visibility in Ayurveda-based preventive healthcare.
Key Trends in Pharma Q2 FY26
- ✅ Export-driven growth from chronic and API segments.
- ✅ Shift toward efficiency and cost discipline.
- 💡 New partnerships expanding healthcare ecosystem presence.
- ⚠️ Exceptional items impacted profitability in select midcaps.
Valuation & Investment View
- Emcure Pharma: Sustainable EBITDA margins above 20% indicate strong execution.
- Unichem Labs: One-off losses mask underlying operational improvement.
- Anlon Healthcare: High profitability supports healthy valuations.
- Orchid Pharma: Restructuring to remain key monitorable.
- Jeena Sikho Lifecare: Expansion in corporate tie-ups strengthens recurring revenue base.
Investors seeking stable healthcare opportunities can align market entry with setups from Nifty F&O Tip
Investor Takeaway
Gulshan Khera, CFP®, notes that the healthcare and pharma segment continues to display resilience amid global volatility. Operational efficiency, regulatory momentum, and institutional partnerships will remain central to sustained valuation re-rating. Explore market trends at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
